Intensity Therapeutics, Inc. – NASDAQ:INTS
Intensity Therapeutics stock price today
$0.295
-1.67
-85.03%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
Intensity Therapeutics stock price monthly change
-61.30%
month
Intensity Therapeutics stock price quarterly change
-61.30%
quarter
Intensity Therapeutics stock price yearly change
-70.64%
year
Intensity Therapeutics key metrics
Market Cap | 28.69M |
Enterprise value | 560.61K |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | -0.06 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.02 |
Revenue | N/A |
EBITDA | -11.63M |
Income | -13.80M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIntensity Therapeutics stock price history
Intensity Therapeutics stock forecast
Intensity Therapeutics financial statements
Average Price Target
$5
Potential upside: 1594.91%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -3.70M | |
|---|---|---|---|
| Sep 2023 | 0 | -2.32M | |
| Dec 2023 | 282.21K | -3.17M | -1123.69% |
| Mar 2024 | 0 | -4.60M |
| 2024-03-14 | -0.18 | -0.12 |
|---|
| Jun 2023 | 18227963 | 3.09M | 16.98% |
|---|---|---|---|
| Sep 2023 | 16815789 | 904.85K | 5.38% |
| Dec 2023 | 17295000 | 4.13M | 23.9% |
| Mar 2024 | 12408000 | 2.68M | 21.65% |
| Jun 2023 | -238.91K | 0 | -241.83K |
|---|---|---|---|
| Sep 2023 | -5.11M | -8.84M | 20.52M |
| Dec 2023 | -947.16K | 2.82M | -12.16K |
| Mar 2024 | -4.36M | 3.26M | 8K |
Intensity Therapeutics alternative data
| Aug 2023 | 4 |
|---|---|
| Sep 2023 | 4 |
| Oct 2023 | 4 |
| Nov 2023 | 4 |
| Dec 2023 | 4 |
| Jan 2024 | 4 |
| Feb 2024 | 4 |
| Mar 2024 | 5 |
| Apr 2024 | 5 |
| May 2024 | 5 |
| Jun 2024 | 5 |
| Jul 2024 | 5 |
Intensity Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|
-
What's the price of Intensity Therapeutics stock today?
One share of Intensity Therapeutics stock can currently be purchased for approximately $0.3.
-
When is Intensity Therapeutics's next earnings date?
Unfortunately, Intensity Therapeutics's (INTS) next earnings date is currently unknown.
-
Does Intensity Therapeutics pay dividends?
No, Intensity Therapeutics does not pay dividends.
-
How much money does Intensity Therapeutics make?
Intensity Therapeutics has a market capitalization of 28.69M. Intensity Therapeutics made a loss 10.54M US dollars in net income (profit) last year or -$0.12 on an earnings per share basis.
-
What is Intensity Therapeutics's stock symbol?
Intensity Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "INTS".
-
What is Intensity Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Intensity Therapeutics?
Shares of Intensity Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Intensity Therapeutics have?
As Jul 2024, Intensity Therapeutics employs 5 workers.
-
When Intensity Therapeutics went public?
Intensity Therapeutics, Inc. is publicly traded company for more then 2 years since IPO on 30 Jun 2023.
-
What is Intensity Therapeutics's official website?
The official website for Intensity Therapeutics is intensitytherapeutics.com.
-
Where are Intensity Therapeutics's headquarters?
Intensity Therapeutics is headquartered at 61 Wilton Road, Westport, CT.
-
How can i contact Intensity Therapeutics?
Intensity Therapeutics's mailing address is 61 Wilton Road, Westport, CT and company can be reached via phone at +20 3 2217381.
-
What is Intensity Therapeutics stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Intensity Therapeutics in the last 12 months, the avarage price target is $5. The average price target represents a 1594.91% change from the last price of $0.3.
Intensity Therapeutics company profile:
Intensity Therapeutics, Inc.
intensitytherapeutics.comExchange:
NASDAQ
Full time employees:
5
Industry:
Biotechnology
Sector:
Healthcare
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
61 Wilton Road
Westport, CT 06880
Westport, CT 06880
CIK: 0001567264
ISIN: US45828J1034
:
